New combination for advanced non-squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer that is not the squamous type and has not been previously treated.
- You are able to do daily activities on your own or with minimal help (ECOG 0-1).
- You do not have certain gene changes (EGFR or ALK) that would make other targeted treatments a better fit.
- You can provide a tumor sample to check for PD-L1, and you have at least one measurable tumor (not just in the brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (BL-B01D1 plus a bispecific antibody) against the current standard chemotherapy and immunotherapy. It aims to see if the new combination works better for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new drug called HB0025 combined with chemotherapy as the first treatment for advanced squamous non-small cell lung cancer that cannot be removed with surgery. It compares this combination to a standard treatment using another drug called pembrolizumab plus chemotherapy.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.